A Phase 2 clinical trial of ATL1102, Antisense Therapeutics’ investigational therapy for Duchenne muscular dystrophy (DMD), recently received authorization to…
Articles by Margarida Azevedo, MSc
Santhera Pharmaceuticals recently launched an expanded access program (EAP) to allow certain Duchenne muscular dystrophy (DMD) patients in the U.S. to…
The U.S. Food and Drug Administration (FDA) recently granted the gene therapy BB-301 orphan drug status for the treatment…
Santhera Pharmaceuticals has started a campaign to help Duchenne muscular dystrophy patients and their families learn more about the breathing challenges…
Through Dec. 31, Parent Project Muscular Dystrophy (PPMD) will match all donations to expand its ongoing Gene Therapy…
Clay Matthews of the Green Bay Packers took to the field in Week 13 of the NFL season wearing a…
The first healthy subject was dosed in a Phase 1b clinical trial evaluating the safety, tolerability and drug properties of …
Duchenne UK has teamed up with five pharmaceutical companies to start Project HERCULES, a collaboration aimed at persuading the national…
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a micro-dystrophin gene therapy program…
The Hope for Gus Foundation and its signature Everest to End Duchenne fundraising trek to Mount Everest…